

Publikationsliste

1. Zamboglou C, Aebersold DM, Albrecht C, Boehmer D, Ganswindt U, Schmidt-Hegemann N-S, et al. The risk of second malignancies following prostate cancer radiotherapy in the era of conformal radiotherapy: a statement of the Prostate Cancer Working Group of the German Society of Radiation Oncology (DEGRO). *Strahlentherapie und Onkologie*. 2024;1-7.
2. Pinkawa M, Haddad H, Schlenter M, Hermani H, Ho H, Kovács A, et al. Application of a Radiopaque Viscous Hydrogel Spacer for Prostate Cancer Radiation Therapy: A Prospective Phase 2 Study. *Practical Radiation Oncology*. 2024;14(1):57-64.
3. Pinkawa M, Boström J, Temming S, Schäfer A, Kovács A, Boström A. Regression of all untreated lesions in multifocal low-grade meningioma following fractionated stereotactic radiotherapy—abscopal effect or spontaneous regression? Case report and review of the literature. *Strahlentherapie und Onkologie*. 2024;1-6.
4. Körber SA, Höcht S, Aebersold D, Albrecht C, Boehmer D, Ganswindt U, et al. Prostate cancer and elective nodal radiation therapy for cN0 and pN0—a never ending story? Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO). *Strahlentherapie und Onkologie*. 2024;200(3):181-7.
5. Spohn SK, Draulans C, Kishan AU, Spratt D, Ross A, Maurer T, et al. Genomic classifiers in personalized prostate cancer radiation therapy approaches: a systematic review and future perspectives based on international consensus. *International Journal of Radiation Oncology* Biology* Physics*. 2023;116(3):503-20.
6. Seymour ZA, Pinkawa M, Daignault-Newton S, Bosch W, Michalski JM, Gay H, et al. A pooled long-term follow-up after radiotherapy for prostate cancer with and without a rectal hydrogel spacer: impact of hydrogel on decline in sexual quality of life. *Frontiers in oncology*. 2023;13:1239104.
7. Pinkawa M, Haddad H, Schlenter M, Ho H, Kovacs A, Hermani H, et al. Application of a Radiopaque Viscous Hydrogel Spacer for Prostate Cancer Radiotherapy—A Prospective Multi-Institutional Phase II Study. *International Journal of Radiation Oncology, Biology, Physics*. 2023;117(2):e428-e9.
8. Haddad H, Hermani H, Hanitzsch H, Heidrich A, Pinkawa M. Dose Distribution of High Dose-Rate and Low Dose-Rate Prostate Brachytherapy at Different Intervals—Impact of a Hydrogel Spacer and Prostate Volume. *Cancers*. 2023;15(5):1396.
9. Bamias A, Stenzl A, Brown SL, Albiges L, Babjuk M, Birtle A, et al. Definition and diagnosis of oligometastatic bladder cancer: a Delphi consensus study endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society Of Medical Oncology Genitourinary Faculty. *European Urology*. 2023;84(4):381-9.
10. Pinkawa M, Hermani H, Bischoff P, Hanitzsch H, Heidrich A, Schäfer A, et al. Focal injection of a radiopaque viscous spacer before focal brachytherapy as re-irradiation for locally recurrent prostate cancer. *Brachytherapy*. 2022;21(6):848-52.
11. Müller A-C, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, et al. Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases. *Strahlentherapie und Onkologie*. 2022;198(8):683-9.
12. Kovács A, Bischoff P, Haddad H, Zhou W, Temming S, Schäfer A, et al. Long-term comparative study on the local tumour control of different ablation technologies in primary and secondary liver malignancies. *Journal of Personalized Medicine*. 2022;12(3):430.
13. Haddad H, Hermani H, Oji N, Temming S, Pinkawa M. MSS11 Presentation Time: 4: 35 PM: Evaluation of Autocontouring in the Interstitial HDR Brachytherapy of Liver Tumors. *Brachytherapy*. 2022;21(6):S48-S9.
14. Haddad H, Hermani H, Bischoff P, Hanitzsch H, Heidrich A, Schaefer A, et al. Permanent interstitial brachytherapy for prostate cancer implementing neoadjuvant prostatic artery embolization. *Brachytherapy*. 2022;21(3):308-16.

15. Borkowetz A, Blana A, Böhmer D, Cash H, Ehrmann U, Franiel T, et al. German S3 evidence-based guidelines on focal therapy in localized prostate cancer: the first evidence-based guidelines on focal therapy. *Urologia internationalis*. 2022;106(5):431-9.
16. Wolf F, Sedlmayer F, Aebbersold D, Albrecht C, Böhmer D, Flentje M, et al. Ultrahypofractionation of localized prostate cancer: Statement from the DEGRO working group prostate cancer. *Strahlentherapie und Onkologie*. 2021;197:89-96.
17. Shelan M, Aebbersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, et al. Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries: A survey of the Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party on Radiation Oncology of the German Cancer Society (DKG-ARO). *Strahlentherapie und Onkologie*. 2021;197(11):993-1000.
18. Rashid A, Pinkawa M, Haddad H, Hermani H, Temming S, Schäfer A, et al. Interstitial single fraction brachytherapy for malignant pulmonary tumours. *Strahlentherapie und Onkologie*. 2021;197:416-22.
19. Pinkawa M, Gharib A, Schlentner M, Timm L, Eble MJ. Quality of life more than 10 years after radiotherapy for localized prostate cancer—impact of time after treatment and prescription dose. *Quality of Life Research*. 2021;30:437-43.
20. Pinkawa M, Aebbersold DM, Böhmer D, Flentje M, Ghadjar P, Schmidt-Hegemann N-S, et al. Radiotherapy in nodal oligorecurrent prostate cancer. *Strahlentherapie und Onkologie*. 2021;197(7):575-80.
21. Pinkawa M. Spinal cord reirradiation-balancing benefit against risks. *Int J Radiat Oncol Biol Phys*. 2021;109:312-3.
22. Payne HA, Pinkawa M, Peedell C, Bhattacharyya SK, Woodward E, Miller LE. SpaceOAR hydrogel spacer injection prior to stereotactic body radiation therapy for men with localized prostate cancer: A systematic review. *Medicine*. 2021;100(49):e28111.
23. Leufgens F, Gharib A, Schlentner M, Timm L, Pinkawa M. Consequential late effects up to > 10 years following primary and postoperative radiotherapy for prostate cancer. *Radiotherapy and Oncology*. 2021;156:188-92.
24. Kovács A, Bischoff P, Haddad H, Kovács G, Schaefer A, Zhou W, et al. Personalized image-guided therapies for local malignancies: interdisciplinary options for interventional radiology and interventional radiotherapy. *Frontiers in Oncology*. 2021;11:616058.
25. Jerezek-Fossa BA, Marvaso G, Zaffaroni M, Gugliandolo SG, Zerini D, Corso F, et al. Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. *Cancer treatment reviews*. 2021;98:102206.
26. Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P, et al. Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09/10 randomized phase 3 trial. *European urology*. 2021;80(3):306-15.
27. Armstrong N, Bahl A, Pinkawa M, Ryder S, Ahmadu C, Ross J, et al. SpaceOAR hydrogel spacer for reducing radiation toxicity during radiotherapy for prostate cancer. A systematic review. *Urology*. 2021;156:e74-e85.
28. Seymour ZA, Hamstra DA, Daignault-Newton S, Bosch W, Michalski J, Gay HA, et al. Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: a pooled prospective evaluation of bowel-associated quality of life. *BJU international*. 2020;126(3):367-72.
29. Pirus G, Aebbersold DM, Albrecht C, Böhmer D, Flentje M, Ute G, et al. Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. *Strahlentherapie und Onkologie*. 2020;196(7):589-97.
30. Pinkawa M, Leufgens F, Gharib A, Schlentner M, Eble M. Consequential Late Effects up to 10 years Following Primary and Postoperative Radiotherapy for Prostate Cancer. *International Journal of Radiation Oncology* Biology* Physics*. 2020;108(3):e220.
31. Miller LE, Efsthathiou JA, Bhattacharyya SK, Payne HA, Woodward E, Pinkawa M. Association of the placement of a perirectal hydrogel spacer with the clinical outcomes of men receiving radiotherapy for prostate cancer: a systematic review and meta-analysis. *JAMA Network Open*. 2020;3(6):e208221-e.

32. Leufgens F, Berneking V, Vögeli T-A, Kirschner-Hermanns R, Eble MJ, Pinkawa M. Prediction of survival outcomes following postoperative radiotherapy after radical prostatectomy for prostate cancer. *Acta Oncologica*. 2020;59(2):157-63.
33. Ghadjar P, Aebbersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, et al. Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer: statement from the DEGRO working group prostate cancer. *Strahlentherapie und Onkologie*. 2020;196:589-97.
34. Beck M, Böhmer D, Aebbersold DM, Albrecht C, Flentje M, Ganswindt U, et al. Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer: Statement from the DEGRO working group on prostate cancer. *Strahlentherapie und Onkologie*. 2020;196:109-16.
35. Vanneste BG, Buettner F, Pinkawa M, Lambin P, Hoffmann AL. Ano-rectal wall dose-surface maps localize the dosimetric benefit of hydrogel rectum spacers in prostate cancer radiotherapy. *Clinical and translational radiation oncology*. 2019;14:17-24.
36. Seymour ZA, Pinkawa M, Daignault-Newton S, Bosch W, Michalski JM, Gay H, et al. Long-term Follow-up after Radiotherapy for Prostate Cancer with and without Rectal Hydrogel Spacer: A Pooled Prospective Evaluation of Sexual Function of Men with Good Baseline Sexual Function. *International Journal of Radiation Oncology, Biology, Physics*. 2019;105(1):S97.
37. Mitin T, Henry A, Choudhury A, Chen RC, Pinkawa M, Spratt DE. SBRT for localized prostate cancer: is it ready for take-off? *International Journal of Radiation Oncology, Biology, Physics*. 2019;105(3):618-20.
38. Leufgens F, Berneking V, Vögeli T-A, Kirschner-Hermanns R, Eble MJ, Pinkawa M. Quality of life changes > 10 years after postoperative radiation therapy after radical prostatectomy for prostate cancer. *International Journal of Radiation Oncology* Biology* Physics*. 2019;105(2):382-8.
39. Kovacs A, Pinkawa M. Interventional therapy in malignant conditions of the prostate. *Der Radiologe*. 2019;59(Suppl 1):28-39.
40. Hermani H, Haddad H, Temming S, Budde M, Adamietz I, Pinkawa M. Dosimetric Comparison of Different Dose Calculation Algorithms in CT-Based Interstitial HDR Brachytherapy. *Brachytherapy*. 2019;18(3):S114.
41. Hermani H, Haddad H, Temming S, Budde M, Adamietz I, Pinkawa M. Dosimetric verification of HDR brachytherapy treatment plans of three different entities based on measurements with a 2D-Array. *Brachytherapy*. 2019;18(3):S113.
42. Ghadjar P, Fiorino C, af Rosenschöld PM, Pinkawa M, Zilli T, van Der Heide UA. ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer. *Radiotherapy and Oncology*. 2019;141:5-13.
43. Choudhury A, Chen RC, Henry A, Mistry H, Mitin T, Pinkawa M, et al. STAMPEDE: Is radiation therapy to the primary a new standard of care in men with metastatic prostate cancer? *International journal of radiation oncology, biology, physics*. 2019;104(1):33-5.
44. van Wijk Y, Vanneste BG, Jochems A, Walsh S, Oberije CJ, Pinkawa M, et al. Development of an isotoxic decision support system integrating genetic markers of toxicity for the implantation of a rectum spacer. *Acta Oncologica*. 2018;57(11):1499-505.
45. Schlenter M, Berneking V, Krenkel B, Mottaghy FM, Vögeli T-A, Eble MJ, et al. Intensitätsmodulierte Radiotherapie des Prostatakarzinoms mit simultanem integriertem Boost nach molekularer Bildgebung mit 18F-Cholin-PET/CT: Klinische Ergebnisse und Lebensqualität. *Strahlentherapie und Onkologie*. 2018;194:638-45.
46. Schlenter M, Berneking V, Krenkel B, Mottaghy FM, Thomas-Alexander V, Eble MJ, et al. Intensity-modulated radiotherapy of prostate cancer with simultaneous integrated boost after molecular imaging with 18F-choline-PET/CT. *Strahlentherapie und Onkologie*. 2018;194(7):638-45.
47. Pinkawa M, Schubert C, Escobar-Corral N, Berneking V, Eble M. Optimization of prostate cancer radiotherapy using of a spacer gel, volumetric modulated arc therapy and a single biological organ at risk objective. *International Journal of Radiation Research*. 2018;16(2):169-76.
48. Pinkawa M. Correspondence (letter to the editor): Radiotherapy. *Deutsches Ärzteblatt International*. 2018;115(35-36):596.

49. Freiberger C, Berneking V, Vögeli T-A, Kirschner-Hermanns R, Eble MJ, Pinkawa M. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer. *Brachytherapy*. 2018;17(3):517-23.
50. van Wijk Y, Vanneste BG, Walsh S, van der Meer S, Ramaekers B, van Elmpt W, et al. Development of a virtual spacer to support the decision for the placement of an implantable rectum spacer for prostate cancer radiotherapy: Comparison of dose, toxicity and cost-effectiveness. *Radiotherapy and Oncology*. 2017;125(1):107-12.
51. Schlenter M, Berneking V, Krenkel B, Mottaghy F, Voegeli T, Eble M, et al. Intensity modulated Prostate Cancer Radiotherapy with simultaneous integrated Boost after molecular imaging with F-choline-PET-CT-clinical Outcomes and Quality of Life. *Strahlentherapie Und Onkologie*. 2017;193:S19-S.
52. Pinkawa M, Berneking V, Schlenter M, Krenkel B, Eble MJ. Quality of life after radiation therapy for prostate cancer with a hydrogel spacer: 5-year results. *International Journal of Radiation Oncology* Biology* Physics*. 2017;99(2):374-7.
53. Pinkawa M, Berneking V, Schlenter M, Krenkel B, Eble M. Quality of Life after Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: Five Year Results. *International Journal of Radiation Oncology, Biology, Physics*. 2017;99(2):S206.
54. Pinkawa M, Berneking V, König L, Frank D, Bretgeld M, Eble MJ. Hydrogelinjektion vermindert die rektale Toxizität nach Radiotherapie bei lokalisiertem Prostatakarzinom. *Strahlentherapie und Onkologie*. 2017;193:22-8.
55. Pinkawa M, Berneking V, König L, Frank D, Bretgeld M, Eble MJ. Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer. *Strahlentherapie und Onkologie*. 2017;193(1):22.
56. Pinkawa M. Salvage treatment options for recurrent seminoma? *International Journal of Radiation Oncology, Biology, Physics*. 2017;99(3):510.
57. Pinkawa M. Benefit from local treatment of the primary tumor in patients with metastatic prostate cancer at diagnosis. *Journal of Xiangya Medicine*. 2017;2(8).
58. Pinkawa M. Zoledronic acid in first-line treatment of prostate cancer. *International Journal of Radiation Oncology, Biology, Physics*. 2017;97(1):6-8.
59. Padmanabhan R, Pinkawa M, Song DY. Hydrogel spacers in prostate radiotherapy: a promising approach to decrease rectal toxicity. *Future Oncology*. 2017;13(29):2697-708.
60. Freiberger C, Berneking V, Vögeli T-A, Kirschner-Hermanns R, Eble MJ, Pinkawa M. Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer—focus on overall survival. *Radiation Oncology*. 2017;12:1-7.
61. Vanneste BG, Hoffmann AL, van Lin EN, Van De Voorde L, Pinkawa M, Lambin P. Who will benefit most from hydrogel rectum spacer implantation in prostate cancer radiotherapy? A model-based approach for patient selection. *Radiotherapy and Oncology*. 2016;121(1):118-23.
62. Vanneste B, Buettner F, Pinkawa M, Lambin P, Hoffmann A. PO-0863: Localizing the benefit of a hydrogel rectum spacer for prostate IMRT within the ano-rectal wall. *Radiotherapy and Oncology*. 2016;1(119):S412.
63. van der Meer S, Vanneste B, Herfs D, van Elmpt W, Schubert C, Pinkawa M, et al. A novel method to predict a priori the toxicity reduction of a prostate-rectum spacer: Virtual Rectum Spacer. *Radiotherapy and Oncology*. 2016;1(118):S105-S6.
64. Piroth MD, Petz D, Pinkawa M, Holy R, Eble MJ. Nutzen eines thermoplastischen Büstenhalters bei Radiotherapie eines Mammakarzinoms: Eine prospektive Analyse. *Strahlentherapie und Onkologie*. 2016;192:609-16.
65. Piroth MD, Petz D, Pinkawa M, Holy R, Eble MJ. Usefulness of a thermoplastic breast bra for breast cancer radiotherapy. *Strahlentherapie und Onkologie*. 2016;192(9):609.
66. Piroth MD, Galldiks N, Pinkawa M, Holy R, Stoffels G, Ermert J, et al. Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume. *Radiation oncology*. 2016;11:1-9.

67. Pinkawa M, Schmitt V, Djukic V, Klotz J, König L, Frank D, et al. PO-0738: Hydrogel injection prevents long-term rectal toxicity after radiotherapy for prostate cancer. *Radiotherapy and Oncology*. 2016;1(119):S345.
68. Pinkawa M, Brzozowska K, Kriehuber R, Eble MJ, Schmitz S. Prediction of radiation-induced toxicity by in vitro radiosensitivity of lymphocytes in prostate cancer patients. *Future Oncology*. 2016;12(5):617-24.
69. Müller A-C, Mischinger J, Klotz T, Gagel B, Habl G, Hatiboglu G, et al. Interdisciplinary consensus statement on indication and application of a hydrogel spacer for prostate radiotherapy based on experience in more than 250 patients. *Radiology and oncology*. 2016;50(3):329-36.
70. Freiberger C, Schmitt V, Eble M, Pinkawa M. Prognostic Significance of Rising Prostate-Specific Antigen (PSA) Levels Following Radiation Therapy for Localized Prostate Cancer—Comparison Between PSA Bounce Versus PSA Recurrence. *International Journal of Radiation Oncology, Biology, Physics*. 2016;96(2):E285-E6.
71. Pinkawa M, Schubert C, Escobar-Corral N, Holy R, Eble MJ. Einsatz eines Hydrogel-Abstandhalters bei der postoperativen Salvage-Radiotherapie des Prostatakarzinoms. *Strahlentherapie und Onkologie*. 2015;191:375-9.
72. Pinkawa M, Schubert C, Escobar-Corral N, Holy R, Eble MJ. Application of a hydrogel spacer for postoperative salvage radiotherapy of prostate cancer. *Strahlenther Onkol*. 2015;191(4):375-9.
73. Pinkawa M, Ribbing C, Djukic V, Klotz J, Holy R, Eble MJ. Frühe hämatologische Veränderungen während der Radiotherapie beim Prostatakarzinom prädiktiv für späte Miktions- und Darmbeschwerden. *Strahlentherapie und Onkologie*. 2015;191:771-7.
74. Pinkawa M, Ribbing C, Djukic V, Klotz J, Holy R, Eble MJ. Early hematologic changes during prostate cancer radiotherapy predictive for late urinary and bowel toxicity. *Strahlentherapie und Onkologie*. 2015;191(10):771.
75. Pinkawa M. Übersicht—Aktuelle Konzepte und Entwicklungen in der Strahlentherapie. *TumorDiagnostik & Therapie*. 2015;36(06):337-40.
76. Pinkawa M. Recent advances in definitive radiotherapy for prostate cancer. *EMJ*. 2015;3(1):41-8.
77. Pinkawa M. Current role of spacers for prostate cancer radiotherapy. *World Journal of Clinical Oncology*. 2015;6(6):189.
78. Uhl M, Herfarth K, Eble MJ, Pinkawa M, van Triest B, Kalisvaart R, et al. Absorbable hydrogel spacer use in men undergoing prostate cancer radiotherapy: 12 month toxicity and proctoscopy results of a prospective multicenter phase II trial. *Radiation Oncology*. 2014;9:1-6.
79. Piroth MD, Fishedick K, Wein B, Heindrichs U, Piroth DM, Holy R, et al. Fat necrosis and parenchymal scarring after breast-conserving surgery and radiotherapy with an intraoperative electron or fractionated, percutaneous boost: a retrospective comparison. *Breast Cancer*. 2014;21:409-14.
80. Pinkawa M, Klotz J, Djukic V, Petz D, Holy R, Eble MJ. Transurethral resection of the prostate after radiotherapy for prostate cancer: impact on quality of life. *International Journal of Urology*. 2014;21(9):899-903.
81. Pinkawa M, Djukic V, Klotz J, Petz D, Piroth MD, Holy R, et al. Hematologic changes during prostate cancer radiation therapy are dependent on the treatment volume. *Future Oncology*. 2014;10(5):835-43.
82. Pinkawa M. Spacer application for prostate cancer radiation therapy. *Future Oncology*. 2014;10(5):851-64.
83. Peinemann F, Labeit AM, Thielscher C, Pinkawa M. Failure to address potential bias in non-randomised controlled clinical trials may cause lack of evidence on patient-reported outcomes: a method study. *BMJ open*. 2014;4(6):e004720.
84. Hatiboglu G, Pinkawa M, Vallée J-P, Uhl M, Hohenfellner M, Hadaschik B. MP46-19 MULTICENTER PHASE II TRIAL OF PERIRECTAL HYDROGEL SPACER APPLICATION IN MEN SCHEDULED FOR DOSE ESCALATION PROSTATE RADIOTHERAPY. *The Journal of Urology*. 2014;191(4S):e517-e8.

85. Yang Y, Ford EC, Wu B, Pinkawa M, Van Triest B, Campbell P, et al. An overlap-volume-histogram based method for rectal dose prediction and automated treatment planning in the external beam prostate radiotherapy following hydrogel injection. *Medical physics*. 2013;40(1):011709.
86. Song DY, Herfarth KK, Uhl M, Eble MJ, Pinkawa M, Van Triest B, et al. A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes. *International Journal of Radiation Oncology* Biology* Physics*. 2013;87(1):81-7.
87. Schmitz S, Pinkawa M, Eble MJ, Kriehuber R. Persisting ring chromosomes detected by mFISH in lymphocytes of a cancer patient—A case report. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*. 2013;756(1-2):158-64.
88. Schmitz S, Brzozowska K, Pinkawa M, Eble M, Kriehuber R. Chromosomal radiosensitivity analyzed by FISH in lymphocytes of prostate cancer patients and healthy donors. *Radiation research*. 2013;180(5):465-73.
89. Pinkawa M, Schoth F, Böhmer D, Hatiboglu G, Sharabi A, Song D, et al. Current standards and future directions for prostate cancer radiation therapy. *Expert review of anticancer therapy*. 2013;13(1):75-88.
90. Pinkawa M, Piroth MD, Holy R, Escobar-Corral N, Caffaro M, Djukic V, et al. Spacer stability and prostate position variability during radiotherapy for prostate cancer applying a hydrogel to protect the rectal wall. *Radiotherapy and Oncology*. 2013;106(2):220-4.
91. Pinkawa M, Klotz J, Djukic V, Schubert C, Escobar-Corral N, Caffaro M, et al. Learning curve in the application of a hydrogel spacer to protect the rectal wall during radiotherapy of localized prostate cancer. *Urology*. 2013;82(4):963-8.
92. Pinkawa M, Klotz J, Djukic V, Bornemann C, Escobar-Corral N, Caffaro M, et al. Learning curve in the application of a hydrogel spacer to protect the rectal wall during radiation therapy of localized prostate cancer. *International Journal of Radiation Oncology, Biology, Physics*. 2013;87(2):S348.
93. Pinkawa M, Bornemann C, Escobar-Corral N, Piroth M, Holy R, Eble M. Behandlungsplanung nach Hydrogelinjektion während Strahlentherapie beim Prostatakarzinom. *Strahlentherapie und Onkologie*. 2013;189:796-800.
94. Pinkawa M, Bornemann C, Escobar-Corral N, Piroth M, Holy R, Eble M. Treatment planning after hydrogel injection during radiotherapy of prostate cancer. *Strahlentherapie und Onkologie*. 2013;189(9):796.
95. Piroth M, Pinkawa M, Holy R, Stoffels G, Coenen H, Langen K, et al. Integration funktioneller PET-Bildgebung zur Bestrahlungsplanung von Patienten mit malignen Gliomen. *Klinische Neurophysiologie*. 2012;43(01):V103.
96. Piroth M, Pinkawa M, Holy R, Klotz J, Schaar S, Stoffels G, et al. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. *Strahlentherapie und Onkologie*. 2012;188(4):334.
97. Pinkawa M, Piroth MD, Holy R, Klotz J, Djukic V, Escobar Corral N, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer-evaluation of quality of life with and without 18 F-choline PET-CT detected simultaneous integrated boost. *Radiation oncology*. 2012;7:1-9.
98. Pinkawa M, Piroth MD, Holy R, Djukic V, Klotz J, Pfister D, et al. Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy. *Radiation Oncology*. 2012;7:1-6.
99. Pinkawa M, Piroth M, Holy R, Escobar-Corral N, Caffaro M, Djukic V, et al. Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer. *Strahlentherapie und Onkologie*. 2012;188(10):917.
100. Pinkawa M, Mottaghy FM, Eble MJ, Piroth MD, Holy R, Klotz J, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer-evaluation of quality of life with and without ¹⁸F-choline PET-CT detected simultaneous integrated boost. *Radiation Oncology (Online)*. 2012;7.
101. Pinkawa M, Holy R, Piroth MD, Klotz J, Pfister D, Heidenreich A, et al. Urinary morbidity after permanent prostate brachytherapy—Impact of dose to the urethra vs. sources placed in close vicinity to the urethra. *Radiotherapy and Oncology*. 2012;103(2):247-51.

102. Pinkawa M, Holy R, Piroth M, Klotz J, Djukic V, Schaar S, et al. PO-0669 BOWEL TOXICITY AFTER IMRT FOR PROSTATE CANCER WITH A SPACER GEL—A MATCHED-PAIR COMPARISON. *Radiotherapy and Oncology*. 2012(103):S261.
103. Peinemann F, Pinkawa M. Treatment of locally advanced prostate cancer: a case report and narrative review. *Case Reports in Urology*. 2012;2012(1):402513.
104. Peinemann F, Grouven U, Bartel C, Sauerland S, Borchers H, Pinkawa M, et al. Permanent interstitial low-dose rate brachytherapy for patients with localized prostate cancer—a systematic review of randomized and non-randomized controlled clinical trials. *EUROPEAN UROLOGY SUPPLEMENTS*. 2012;11(1):E413-U907.
105. Heidenreich A, Wilop S, Pinkawa M, Porres D, Pfister D. Surgical resection of urological tumor metastases following medical treatment. *Deutsches Ärzteblatt International*. 2012;109(39):631.
106. Heidenreich A, Wilop S, Pinkawa M, Porres D, Pfister D. Übersichtsarbeit-Metastasenresektion urologischer Tumoren nach medikamentöser Tumortherapie. *Deutsches Ärzteblatt-Arztliche Mitteilungen-Ausgabe B*. 2012;109(39):631.
107. Hatiboglu G, Pinkawa M, Vallée JP, Hadaschik B, Hohenfellner M. Application technique: placement of a prostate–rectum spacer in men undergoing prostate radiation therapy. *BJU international*. 2012;110(11b):E647-E52.
108. Galldiks N, Langen K-J, Holy R, Pinkawa M, Stoffels G, Nolte KW, et al. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. *Journal of Nuclear Medicine*. 2012;53(7):1048-57.
109. Brzozowska K, Pinkawa M, Eble MJ, Müller W-U, Wojcik A, Kriehuber R, et al. In vivo versus in vitro individual radiosensitivity analysed in healthy donors and in prostate cancer patients with and without severe side effects after radiotherapy. *International journal of radiation biology*. 2012;88(5):405-13.
110. Song D, Herfarth K, Uhl M, van Triest B, Kalisvaart R, Eble M, et al. A Multi-institutional Trial Of Rectal Dose Reduction During Prostate Radiotherapy Via Polyethylene-glycol Hydrogel Injection: Initial Results. *International Journal of Radiation Oncology, Biology, Physics*. 2011;81(2):S412.
111. Piroth MD, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G, et al. Prognostic value of early [18F] fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. *International Journal of Radiation Oncology* Biology* Physics*. 2011;80(1):176-84.
112. Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Galldiks N, et al. Prognostic impact of postoperative, pre-irradiation 18F-fluoroethyl-L-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. *Radiotherapy and Oncology*. 2011;99(2):218-24.
113. Piroth M, Coenen H, Pinkawa M, Langen K, Herzog H, Stoffels G, et al. Prognostic impact of postoperative 18F-fluoroethyl-L-tyrosine uptake in patients with glioblastoma multiforme. *Radiotherapy and oncology*. 2011;99(PreJuSER-16333):218-24.
114. Pinkawa M, Piroth MD, Holy R, Fishedick K, Klotz J, Székely-Orbán D, et al. Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison. *International Journal of Radiation Oncology* Biology* Physics*. 2011;81(1):23-8.
115. Pinkawa M, Piroth MD, Holy R, Djukic V, Klotz J, Krenkel B, et al. Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. *Strahlentherapie und Onkologie*. 2011;187(8):479.
116. Pinkawa M, Holy R, Piroth MD, Klotz J, Pfister D, Heidenreich A, et al. Interpreting the clinical significance of quality of life score changes after radiotherapy for localized prostate cancer. *Current Urology*. 2011;5(3):137-44.
117. Pinkawa M, Holy R, Piroth M, Djukic V, Klotz J, Escobar NC, et al. Dose-escalation using intensity-modulated radiotherapy (IMRT) for prostate cancer-evaluation of quality of life (QoL) with and without ¹⁸F-choline PET-CT detected simultaneous integrated boost (SIB). *Strahlentherapie Und Onkologie*. 2011;187(9):598-.
118. Pinkawa M, Eble MJ, Mottaghy FM. PET and PET/CT in radiation treatment planning for prostate cancer. Expert review of anticancer therapy. 2011;11(7):1035-41.

119. Pinkawa M, Djukic V, Holy R, Piroth M, Klotz J, Frank D, et al. Application of a spacer between prostate and anterior rectal wall to optimize radiotherapy of localized prostate cancer. *Strahlenther Onkol.* 2011;187(1):42-3.
120. Pinkawa M, Corral NE, Caffaro M, Piroth MD, Holy R, Djukic V, et al. Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. *Radiotherapy and Oncology.* 2011;100(3):436-41.
121. Pinkawa M, Corral NE, Caffaro M, Piroth M, Holy R, Otto G, et al. Application of a Spacer between Prostate and Anterior Rectal Wall to Optimize Radiotherapy of Localized Prostate Cancer: Comparison of Three-dimensional Conformal (3D RT) and Intensity Modulated (IMRT) Treatment Planning Techniques. *International Journal of Radiation Oncology, Biology, Physics.* 2011;81(2):S398-S9.
122. Peinemann F, Grouven U, Hemkens LG, Bartel C, Borchers H, Pinkawa M, et al. Low-dose rate brachytherapy for men with localized prostate cancer. *Cochrane Database of Systematic Reviews.* 2011(7).
123. Peinemann F, Grouven U, Bartel C, Sauerland S, Borchers H, Pinkawa M, et al. Platinum Priorities. *European urology.* 2011;60(5).
124. Peinemann F, Grouven U, Bartel C, Sauerland S, Borchers H, Pinkawa M, et al. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. *European urology.* 2011;60(5):881-93.
125. Holy R, Piroth M, Pinkawa M, Eble MJ. Behandlung von Nebennierenmetastasen nichtkleinzelliger Bronchialkarzinome mit extrakranieller stereotaktischer Strahlentherapie (ESRT). *Strahlentherapie und Onkologie.* 2011;187:245-51.
126. Holy R, Piroth M, Pinkawa M, Eble MJ. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. *Strahlentherapie und Onkologie.* 2011;187(4):245.
127. Piroth M, Heindrichs U, Pinkawa M, Piroth D, Schmachtenberg A, Perez-Bouza A, et al. Intraoperative Radiotherapie (IORT) des Mammakarzinoms mit Elektronen—eigene Erfahrungen, aktuelle Aspekte und Literaturübersicht. *Geburtshilfe und Frauenheilkunde.* 2010;70(03):219-25.
128. Piroth M, Heindrichs U, Pinkawa M, Piroth D, Schmachtenberg A, Perez-Bouza A, et al. Intraoperative Radiotherapy (IORT) with Electrons for Breast Cancer—Our Experience, Current Considerations and Review of the Literature. *Geburtshilfe und Frauenheilkunde.* 2010;70(03):219-25.
129. Pinkawa M, Piroth MD, Holy R, Klotz J, Nussen S, Borchers H, et al. Rectal morbidity after permanent interstitial brachytherapy for prostate cancer—Impact of Day 1 vs. Day 30 computed tomography—based postimplant dosimetry. *Brachytherapy.* 2010;9(1):1-7.
130. Pinkawa M, Piroth MD, Holy R, Fishedick K, Schaar S, Borchers H, et al. Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer. *Radiotherapy and oncology.* 2010;96(1):25-9.
131. Pinkawa M, Holy R, Piroth MD, Klotz J, Nussen S, Krohn T, et al. Intensitätsmodulierte Radiotherapie des Prostatakarzinoms mit simultanem integrierten Boost nach molekularer Bildgebung mit 18 F-Cholin-PET-CT. *Strahlentherapie und Onkologie.* 2010;186:600-6.
132. Pinkawa M, Holy R, Piroth MD, Klotz J, Nussen S, Krohn T, et al. Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost. *Strahlentherapie und Onkologie.* 2010;186(11):600.
133. Pinkawa M, Holy R, Piroth MD, Fishedick K, Schaar S, Székely-Orbán D, et al. Consequential late effects after radiotherapy for prostate cancer—a prospective longitudinal quality of life study. *Radiation Oncology.* 2010;5:1-9.
134. Pinkawa M, Holy R, Piroth M, Klotz J, Nussen S, Krohn T, et al. Intensity-modulated radiotherapy of prostate carcinoma with simultaneous integrated boost for molecular imaging with ¹⁸F-choline PET-CT. *Strahlentherapie Und Onkologie.* 2010;186:56-7.
135. Pinkawa M. External beam radiotherapy for prostate cancer. *Panminerva medica.* 2010;52(3):195-207.

136. Holy R, Torres I, Georgi J, Krohn T, Winz O, Pinkawa M, et al. Implementation of respiratory motion estimation from PET imaging data in the planning process of highly focused irradiation for lung tumors. *Strahlentherapie Und Onkologie*. 2010;186:145-6.
137. Volz-Sidiropoulou E, Pinkawa M, Fishedick K, Jakse G, Gauggel S, Eble MJ. Factor analysis of the expanded prostate cancer index composite in a patient group after primary (external beam radiotherapy and permanent Iodine-125 brachytherapy) and postoperative radiotherapy for prostate cancer. *Current Urology*. 2009;2(3):122-9.
138. Piroth MD, Piroth DM, Pinkawa M, Woodruff SG, Holy R, Eble MJ. Immediate reconstruction with an expander/implant following ablatio mammae because of breast cancer. *Strahlentherapie und Onkologie*. 2009;185(10):669.
139. Piroth MD, Pinkawa M, Holy R, Stoffels G, Demirel C, Attieh C, et al. Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme—a dosimetric comparison. *Radiation Oncology*. 2009;4:1-12.
140. Pinkawa M, Piroth MD, Fishedick K, Nussen S, Klotz J, Holy R, et al. Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer—predictive factors on irritative symptoms, incontinence and rectal bleeding. *Radiation Oncology*. 2009;4:1-10.
141. Pinkawa M, Piroth MD, Fishedick K, Holy R, Klotz J, Nussen S, et al. Einfluss des Zielvolumens (Prostata allein vs. Prostata mit Samenblasen) und der Einzeldosis (1.8 Gy vs. 2.0 Gy) auf Veränderungen der Lebensqualität nach perkutaner Radiotherapie des Prostatakarzinoms. *Strahlentherapie und Onkologie*. 2009;185:724-30.
142. Pinkawa M, Piroth MD, Fishedick K, Holy R, Klotz J, Nussen S, et al. Impact of the target volume (prostate alone vs. prostate with seminal vesicles) and fraction dose (1.8 Gy vs. 2.0 Gy) on quality of life changes after external-beam radiotherapy for prostate cancer. *Strahlentherapie und Onkologie*. 2009;185(11):724.
143. Pinkawa M, Piroth MD, Asadpour B, Gagel B, Fishedick K, Siluscsek J, et al. Neoadjuvant hormonal therapy and external-beam radiotherapy versus external-beam irradiation alone for prostate cancer. *Strahlentherapie und Onkologie*. 2009;185(2):101-8.
144. Pinkawa M, Piroth MD, Asadpour B, Gagel B, Fishedick K, Siluscsek J, et al. Neoadjuvante Hormontherapie und perkutane Radiotherapie versus alleinige perkutane Radiotherapie beim Prostatakarzinom. Eine Lebensqualitätsanalyse: A quality-of-life analysis. *Strahlentherapie und Onkologie*. 2009;185:101-8.
145. Pinkawa M, Gontero P. The motion: radiotherapy for prostate cancer preserves sexual function to a greater extent than nerve sparing radical prostatectomy. *European urology*. 2009;56(1):212-4.
146. Pinkawa M, Gagel B, Piroth MD, Fishedick K, Asadpour B, Kehl M, et al. Erectile dysfunction after external beam radiotherapy for prostate cancer. *European urology*. 2009;55(1):227-36.
147. Pinkawa M, Fishedick K, Gagel B, Piroth MD, Asadpour B, Klotz J, et al. Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment. *BMC cancer*. 2009;9:1-10.
148. Pinkawa M, Attieh C, Piroth MD, Holy R, Nussen S, Klotz J, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer—evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost. *Radiotherapy and Oncology*. 2009;93(2):213-9.
149. Pinkawa M, Asadpour B, Piroth MD, Gagel B, Nussen S, Kehl M, et al. Health-related quality of life after permanent I-125 brachytherapy and conformal external beam radiotherapy for prostate cancer—a matched-pair comparison. *Radiotherapy and oncology*. 2009;91(2):225-31.
150. Pinkawa M, Asadpour B, Piroth MD, Gagel B, Klotz J, Fishedick K, et al. Rectal dosimetry following prostate brachytherapy with stranded seeds—Comparison of transrectal ultrasound intra-operative planning (day 0) and computed tomography-postplanning (day 1 vs. day 30) with special focus on sources placed close to the rectal wall. *Radiotherapy and Oncology*. 2009;91(2):207-12.
151. Kirschner-Hermanns R, Brehmer B, Borchers H, Kahle C, Eble MJ, Reineke T, et al. Do patients with urodynamically proven infravesical obstruction and detrusor overactivity have a higher risk for

long-term bothersome symptoms after brachytherapy in comparison to patients treated with radical prostatectomy for localized prostate cancer? *Current Urology*. 2009;2(3):135-41.

152. Borchers H, Pinkawa M, Donner A, Wolter TP, Pallua N, Eble MJ, et al. Rectourethral fistula following LDR brachytherapy. *Urologia Internationalis*. 2009;82(3):365-6.

153. Piroth MD, Pinkawa M, Gagel B, Stanzel S, Asadpour B, Eble MJ. Sequencing chemotherapy and radiotherapy in locoregional advanced breast cancer patients after mastectomy—a retrospective analysis. *BMC cancer*. 2008;8:1-9.

154. Pinkawa M, Pursch-Lee M, Asadpour B, Gagel B, Piroth MD, Klotz J, et al. Bildgeführte Radiotherapie beim Prostatakarzinom. Anwendung der ultraschallbasierten Prostatalokalisation zur Analyse der inter-und intrafraktionellen Organbewegung: Implementation of ultrasound-based prostate localization for the analysis of inter-and intrafraction organ motion. *Strahlentherapie und Onkologie*. 2008;184:679-85.

155. Pinkawa M, Pursch-Lee M, Asadpour B, Gagel B, Piroth MD, Klotz J, et al. Image-guided radiotherapy for prostate cancer. *Strahlentherapie und Onkologie*. 2008;184(12):679.

156. Pinkawa M, Gagel B, Asadpour B, Piroth MD, Klotz J, Borchers H, et al. Seedverschiebungen nach permanenter Brachytherapie des Prostatakarzinoms in Abhängigkeit vom Prostatalevel. *Strahlentherapie und Onkologie*. 2008;184:520-5.

157. Pinkawa M, Gagel B, Asadpour B, Piroth MD, Klotz J, Borchers H, et al. Seed displacements after permanent brachytherapy for prostate cancer in dependence on the prostate level. *Strahlentherapie und Onkologie*. 2008;10(184):520-5.

158. Pinkawa M, Gagel B, Asadpour B, Piroth M, Klotz J, Borchers H, et al. Seed Displacements after Permanent I-125 Brachytherapy for Prostate Cancer-Comparison of Seeds in Different Prostate Areas. *International Journal of Radiation Oncology, Biology, Physics*. 2008;72(1):S347.

159. Pinkawa M, Fishedick K, Asadpour B, Gagel B, Piroth MD, Nussen S, et al. Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer. *International Journal of Radiation Oncology* Biology* Physics*. 2008;70(1):83-9.

160. Pinkawa M, Fishedick K, Asadpour B, Gagel B, Piroth MD, Holy R, et al. Health-related quality of life after adjuvant and salvage postoperative radiotherapy for prostate cancer—a prospective analysis. *Radiotherapy and Oncology*. 2008;88(1):135-9.

161. Piroth MD, Gagel B, Pinkawa M, Stanzel S, Asadpour B, Eble MJ. Postoperative radiotherapy of glioblastoma multiforme. *Strahlentherapie und Onkologie*. 2007;183(12):695.

162. Piroth MD, Gagel B, Pinkawa M, Stanzel S, Asadpour B, Eble MJ. Postoperative Strahlentherapie des Glioblastoma multiforme. Analyse und kritische Bewertung verschiedener Behandlungsstrategien und prädiktiver Faktoren: Analysis and Critical Assessment of Different Treatment Strategies and Predictive Factors. *Strahlentherapie und Onkologie*. 2007;183:695-702.

163. Pinkawa M, Siluscek J, Gagel B, Piroth MD, Demirel C, Asadpour B, et al. Postoperative Radiotherapie beim Prostatakarzinom. Untersuchung von Zielvolumenveränderungen und Behandlungstechniken (intensitätsmodulierte versus konformale Radiotherapie) Evaluation of Target Motion and Treatment Techniques (Intensity-Modulated Versus Conformal Radiotherapy). *Strahlentherapie und Onkologie*. 2007;183:23-9.

164. Pinkawa M, Siluscek J, Gagel B, Piroth MD, Demirel C, Asadpour B, et al. Postoperative radiotherapy for prostate cancer. *Strahlentherapie und Onkologie*. 2007;183(1):23.

165. Pinkawa M, Fishedick K, Piroth MD, Gagel B, Borchers H, Jakse G, et al. Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy. *Urology*. 2007;69(1):129-33.

166. Pinkawa M, Fishedick K, Asadpour B, Piroth M, Gagel B, Krenkel B, et al. Do patients with larger prostates have greater toxicity after external beam radiotherapy for localized prostate cancer? *Journal of Clinical Oncology*. 2007;25(18_suppl):15577-.

167. Pinkawa M, Asadpour B, Siluscek J, Gagel B, Piroth MD, Demirel C, et al. Bladder extension variability during pelvic external beam radiotherapy with a full or empty bladder. *Radiotherapy and oncology*. 2007;83(2):163-7.

168. Pinkawa M, Asadpour B, Gagel B, Piroth MD, Borchers H, Jakse G, et al. Evaluation of source displacement and dose–volume changes after permanent prostate brachytherapy with stranded seeds. *Radiotherapy and Oncology*. 2007;84(2):190-6.
169. Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Kaiser HJ, et al. pO polarography, contrast enhanced color duplex sonography (CDS), [18 F] fluoromisonidazole and [18 F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? *BMC cancer*. 2007;7:1-9.
170. Gagel B, Piroth M, Pinkawa M, Reinartz P, Krohn T, Kaiser HJ, et al. Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study. *BMC cancer*. 2007;7:1-10.
171. Gagel B, Pinkawa M, Stanzel S, Asadpour B, Eble M. Postoperative Radiotherapy of Glioblastoma Multiforme. *Strahlentherapie und Onkologie*. 2007;183(12).
172. Gagel B, Hamacher K, Coenen HH, Scholbach T, Maneschi P, DiMartino E, et al. pO polarography, contrast enhanced color duplex sonography (CDS), [¹⁸ F] fluoromisonidazole and [¹⁸ F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? *BMC cancer* (Online). 2007;7.
173. Gagel B, Demirel C, Kientopf A, Pinkawa M, Piroth M, Stanzel S, et al. Active breathing control (ABC): determination and reduction of breathing-induced organ motion in the chest. *International Journal of Radiation Oncology* Biology* Physics*. 2007;67(3):742-9.
174. Pinkawa M, Siluscheck J, Gagel B, Demirel C, Asadpour B, Holy R, et al. Influence of the initial rectal distension on posterior margins in primary and postoperative radiotherapy for prostate cancer. *Radiotherapy and oncology*. 2006;81(3):284-90.
175. Pinkawa M, Gagel B, Piroth MD, Borchers H, Jakse G, Eble MJ. Changes of dose delivery distribution within the first month after permanent interstitial brachytherapy for prostate cancer. *Strahlentherapie und Onkologie*. 2006;182(9):525.
176. Pinkawa M, Fishedick K, Treusacher P, Asadpour B, Gagel B, Piroth MD, et al. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer—a phase II study. *Radiotherapy and oncology*. 2006;78(1):41-6.
177. Pinkawa M, Fishedick K, Piroth MD, Gagel B, Borchers H, Jakse G, et al. Lebensqualität nach permanenter interstitieller Brachytherapie beim Prostatakarzinom. Korrelation mit Parametern des Postimplantations-CT: Correlation with Postimplant CT Scan Parameters. *Strahlentherapie und Onkologie*. 2006;182:660-5.
178. Pinkawa M, Fishedick K, Piroth MD, Gagel B, Borchers H, Jakse G, et al. Health-related quality of life after permanent interstitial brachytherapy for prostate cancer. *Strahlentherapie und Onkologie*. 2006;182(11):660.
179. Pinkawa M, Fishedick K, Gagel B, Piroth MD, Borchers H, Jakse G, et al. Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer. *Urology*. 2006;68(1):104-9.
180. Pinkawa M, Fishedick K, Asadpour B, Gagel B, Piroth MD, Eble MJ. Low-grade toxicity after conformal radiation therapy for prostate cancer—impact of bladder volume. *International Journal of Radiation Oncology* Biology* Physics*. 2006;64(3):835-41.
181. Pinkawa M, Asadpour B, Gagel B, Piroth MD, Holy R, Eble MJ. Prostate position variability and dose–volume histograms in radiotherapy for prostate cancer with full and empty bladder. *International Journal of Radiation Oncology* Biology* Physics*. 2006;64(3):856-61.
182. Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M, et al. [18 F] fluoromisonidazole and [18 F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. *BMC cancer*. 2006;6:1-8.
183. Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Fishedick K, et al. Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer. *Strahlentherapie und Onkologie*. 2006;182(5):263.

184. Gagel B, DiMartino E, Schramm O, Pinkawa M, Piroth M, Demirel C, et al. Contrast-enhanced color duplex sonography (CDS): an alternative for the evaluation of therapy-relevant tumor oxygenation? *Strahlentherapie und Onkologie*. 2006;182(10):604.
185. Gagel B, DiMartino E, Schramm O, Pinkawa M, Piroth M, Demirel C, et al. Kontrastangehobene, farbkodierte Duplexsonographie (CDS): eine Alternative zur Bestimmung der therapierelevanten Tumoroxygenierung? *Strahlentherapie und Onkologie*. 2006;182:604-9.
186. Gagel B, Reinartz P, DiMartino E, Zimny M, Pinkawa M, Maneschi P, et al. pO₂-Polarographie versus Positronenemissionstomographie ([¹⁸F]-Fluormisonidazol,[¹⁸F]-Fluorodeoxyglucose). Eine Bewertung der strahlentherapeutisch relevanten Hypoxie: An Appraisal of Radiotherapeutically Relevant Hypoxia. *Strahlentherapie und Onkologie*. 2004;180:616-22.
187. Gagel B, Pinkawa M, Maneschi P, Eble M, Reinartz P, Zimny M, et al. pO₂ polarography versus positron emission tomography ([¹⁸F] fluoromisonidazole,[¹⁸F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. *Strahlentherapie und Onkologie*. 2004;180.
188. Borchers H, Kirschner-Hermanns R, Brehmer B, Tietze L, Reineke T, Pinkawa M, et al. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results. *BJU international*. 2004;94(6):805-11.
189. Pinkawa M, Maurer U, Mulhern A, Gagel B, Block T, Borchers H, et al. Inverse automatische Bestrahlungsplanung mit und ohne individuelle Optimierung bei der interstitiellen permanenten Brachytherapie des Prostatakarzinoms mit 125 J hoher und niedriger Aktivität. *Strahlentherapie und Onkologie*. 2003;179:417-22.
190. Pinkawa M, Maurer U, Mulhern A, Gagel B, Block T, Borchers H, et al. Inverse automated treatment planning with and without individual optimization in interstitial permanent prostate brachytherapy with high-and low-activity 125I. *Strahlentherapie und Onkologie*. 2003;179(6):417.
191. Pinkawa M, Gagel B, Demirel C, Schmachtenberg A, Asadpour B, Eble MJ. Dose-volume histogram evaluation of prone and supine patient position in external beam radiotherapy for cervical and endometrial cancer. *Radiotherapy and oncology*. 2003;69(1):99-105.
192. Pinkawa M, Fishedick K, Maurer U, Borchers H, Jakse G, Eble M. Subacute and late toxicity after interstitial permanent, interstitial temporary and external irradiation of the prostate. *International Journal of Radiation Oncology, Biology, Physics*. 2003;57(2):S228-S9.
193. Maurer U, Block T, Koehn G, Czempel H, Pinkawa M, Gagel B, et al. Evaluation of D90 and V100 with intraoperative trus-online-dosimetry in patients with prostate cancer (PC) during seed implantation. *International Journal of Radiation Oncology, Biology, Physics*. 2002;54(2):255-6.